Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.33 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.33 |
| ▸ | WNT1 | P04628 | 3/20 | 0.33 |
| ▸ | GSK3B | P49841 | 3/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.33 |
| ▸ | CLK2 | P49760 | 2/20 | 0.33 |
| ▸ | CLK3 | P49761 | 2/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.33 |
| ▸ | GCGR | P47871 | 2/20 | 0.32 |
| ▸ | GIPR | P48546 | 2/20 | 0.32 |
| ▸ | ABL1 | P00519 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20162139 | 0.88 | SCD (0.51) | SCDHTR2CTAS2R8ENPP2ABL1 | |
| SCHEMBL20162128 | 0.88 | PTGER1 (0.44) | SCDTAS2R8PTGER1WNT1GSK3B | |
| SCHEMBL20162143 | 0.88 | TAS2R8 (0.37) | HTR2CTAS2R8PTGER1RIPK1WNT1 | |
| SCHEMBL20162174 | 0.85 | HTR2C (0.43) | HTR2CTAS2R8PTGER1RIPK1WNT1 | |
| SCHEMBL20162155 | 0.83 | TAS2R8 (0.40) | TAS2R8PTGER1RIPK1WNT1GSK3B | |
| SCHEMBL20162150 | 0.83 | HTR2C (0.46) | HTR2CTAS2R8RIPK1 | |
| SCHEMBL20169996 | 0.83 | HTR2C (0.46) | HTR2CTAS2R8PTGER1RIPK1 | |
| SCHEMBL20162116 | 0.82 | TAS2R8 (0.39) | TAS2R8PTGER1RIPK1WNT1GSK3B | |
| SCHEMBL20162161 | 0.81 | RIPK1 (0.40) | SCDHDAC6TAS2R8RIPK1 | |
| SCHEMBL20162175 | 0.81 | TAS2R8 (0.39) | HTR2CTAS2R8PTGER1RIPK1WNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | claimed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | claimed |
| EP-3323809-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-05-23 | — | — | EP | claimed |
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| EP-3323809-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | NR0B1, NR2E1, NR0B2 | SCD 4699/4885HTR2C 1471/4885HDAC3 71/4885 |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | NR0B1, NR2E1, NR0B2 | SCD 4699/4885HTR2C 1471/4885HDAC3 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.